CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,170 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05153187
NCT05153187N/ACompleted

Descriptive Analyses of Clinical Characteristics and Treatment Patterns of Breast Cancer Patients Initiating Palbociclib (Ibrance(Registered)) Treatment in Japan by Using MDV Database

Pfizer·observational·Posted Dec 10, 2021·Updated Apr 21, 2026

In Brief

An observational study for Breast Cancer. Completed, enrolled 1,170 participants across 1 site.

Detailed Summary

This is a retrospective observational study focusing on patients diagnosed with advanced breast cancer(ABC) in Japan using de-identified claim data from Medical Data Vision (MDV) database. The primary objective of this study is to describe patient demographics, treatment patterns and treatment duration of palbociclib, and subsequent treatment patterns and treatment duration after palbociclib-based therapy among ABC patients in Japan The secondary objective of the study is to describe patient demographics, treatment patterns of ABC patients and treatment duration of endocrine therapy, and subsequent treatment patterns and treatment duration after endocrine therapy among ABC patients in Japan.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 10, 2021
Enrollment StartAug 31, 2019
Primary CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.6 years ago